ID: ALA4062918

Max Phase: Preclinical

Molecular Formula: C29H36N6O6

Molecular Weight: 564.64

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)C[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)c1cc(=O)oc2cc(N)ccc12

Standard InChI:  InChI=1S/C29H36N6O6/c1-17(2)13-23(35-29(39)40-16-18-7-4-3-5-8-18)27(38)34-22(9-6-12-33-28(31)32)26(37)21-15-25(36)41-24-14-19(30)10-11-20(21)24/h3-5,7-8,10-11,14-15,17,22-23H,6,9,12-13,16,30H2,1-2H3,(H,34,38)(H,35,39)(H4,31,32,33)/t22-,23-/m0/s1

Standard InChI Key:  BDUPEQLYHUCJJY-GOTSBHOMSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 564.64

Molecular Weight (Monoisotopic): 564.2696

AlogP: 2.65

#Rotatable Bonds: 13

Polar Surface Area: 202.63

Molecular Species: BASE

HBA: 8

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 12

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 12.42

CX Basic pKa: 11.76

CX LogP: 2.09

CX LogD: -0.02

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.05

Np Likeness Score: 0.07

References

1. Xie H, Chen G, Young RN..  (2017)  Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.,  60  (16): [PMID:28699744] [10.1021/acs.jmedchem.6b00951]

Source

Source(1):

• Scientific Literature